What is Primary Hyperaldosteronism?
Primary hyperaldosteronism (PA) is an adrenal disorder causing excessive, autonomous aldosterone production by one or both adrenal glands, independent of the renin-angiotensin system, resulting in hypertension, sodium retention, volume expansion, and often hypokalemia 1.
Pathophysiology
PA represents a primary adrenal problem where aldosterone secretion becomes at least partially autonomous from its normal regulator—the renin-angiotensin system. This autonomy leads to:
- Suppressed renin levels (the hallmark finding)
- Renal sodium retention and volume expansion
- Elevated blood pressure
- Hypokalemia in more severe cases (though many patients remain normokalemic)
The excess aldosterone acts on mineralocorticoid receptors throughout the body, causing hemodynamic changes including increased extracellular volume, elevated cardiac output, and greater arterial stiffness compared to essential hypertension 2.
Clinical Significance and Morbidity
PA is the most common cause of secondary hypertension, affecting 5-10% of all hypertensive patients, rising to 17.8% in young-onset hypertension and 20-30% in resistant hypertension 2. This is not a rare condition—it's a common, underdiagnosed disorder with serious consequences.
Cardiovascular and Renal Risks
Compared to patients with primary hypertension at similar blood pressure levels, individuals with PA face dramatically higher risks 1:
- Stroke: 2.58-fold increased risk
- Coronary artery disease: 1.77-fold increased risk
- Atrial fibrillation: 3.52-fold increased risk
- Heart failure: 2.05-fold increased risk
- Albuminuria: 2.09-fold increased risk
- Proteinuria: 2.68-fold increased risk
Major adverse cardiovascular events occur in 13.6% of PA patients at 5.8 years follow-up 2. These excess risks are aldosterone-mediated and occur independent of blood pressure elevation, meaning standard antihypertensive therapy alone does not fully mitigate the cardiovascular damage.
Quality of Life Impact
Beyond cardiovascular morbidity, PA significantly impairs quality of life:
- Psychiatric comorbidities affect 30-70% of patients, including depression and anxiety, likely related to central mineralocorticoid receptor effects 2
- Sleep disturbances are particularly prominent in females
- Reduced psychological well-being is commonly reported 1
Common Misconceptions (Critical Pitfalls)
PA is NOT defined by hypokalemia, adrenal macro-nodules, frankly elevated aldosterone levels, or severe hypertension 1. These misconceptions contribute to massive underdiagnosis:
- Most PA patients are normokalemic
- Aldosterone levels may be only modestly elevated
- Hypertension severity varies widely
- Adrenal imaging may appear normal
The 2024 European Society of Cardiology guidelines now recommend screening all adults with diagnosed hypertension for PA, reflecting recognition that this condition exists across a spectrum from mild to severe 1.
Etiology and Subtypes
PA encompasses two main categories:
- Unilateral disease (~35-50%): Usually aldosterone-producing adenoma (APA), potentially surgically curable
- Bilateral disease: Idiopathic hyperaldosteronism (IHA), requiring lifelong medical therapy
Somatic mutations in ion channels and pumps (particularly KCNJ5, more common in Asian populations) drive many cases, explaining why PA is so prevalent and suggesting milder, evolving forms exist 3, 2.
Why This Matters Clinically
PA remains markedly underdiagnosed and undertreated despite being common and having effective, targeted treatments 1. The morbidity and mortality are largely preventable:
- Unilateral PA can often be cured with adrenalectomy
- Bilateral PA responds to mineralocorticoid receptor antagonists (MRAs), which control blood pressure, resolve hypokalemia, and reduce excess cardiovascular risk 1
Screening rates remain critically low—fewer than 2% of eligible patients are screened 4—leading to years of suboptimal treatment, preventable cardiovascular events, and reduced quality of life. The updated 2025 Endocrine Society guidelines aim to address this by recommending universal screening with the aldosterone-to-renin ratio (ARR) in all hypertensive patients 1.